

# FORM 5

## QUARTERLY LISTING STATEMENT

Name of Listed Issuer: Jolt Health Inc. (Former Love Pharma Inc. (the "Issuer")).

Trading Symbol: LUV

### 1. Related party transactions

Provide disclosure of all transactions with a Related Person, including those previously disclosed on Form 10. Include in the disclosure the following information about the transactions with Related Persons:

**For the 3-month period ended September 30, 2023 related party transactions were limited management contracts for services provided by certain officers and Directors as further defined in the Financial Statements.**

### 2. Summary of securities issued and options granted during the period.

Provide the following information for the period beginning on the date of the last Listing Statement (Form 2A):

**See financial statements for the 3-month period Ended September 30, 2023 as filed on SEDAR and the CSE site November 2, 2023**

(a) summary of securities issued during the period,

Date of Issue	Type of Security (common shares, convertible debentures, etc.)	Type of Issue (private placement, public offering, exercise of warrants, etc.)	Number	Price	Total Proceeds	Type of Consideration (cash, property, etc.)	Describe relationship of Person with Issuer (indicate if Related Person)	Commission Paid
N/A								

(b) summary of options granted during the period,

Date	Number	Name of Optionee if Related Person and relationship	Generic description of other Optionees	Exercise Price	Expiry Date	Market Price on date of Grant
N/A						

**3. Summary of securities as at the end of the reporting period.**

Provide the following information in tabular format as at the end of the reporting period:

**See financial statements for the 3-month period Ended Septemebr 30, 2023 as filed on SEDAR and the CSE site September 2, 2022**

**4. List the names of the directors and officers, with an indication of the position(s) held, as at the date this report is signed and filed.**

Gerald Tritt – Director & Chief Executive Officer

Doug Taylor – Director

Mark Tommasi – Director

Tatiana Kovaleva– Chief Financial Officer

**SCHEDULE C: MANAGEMENT DISCUSSION AND ANALYSIS**

Provide Interim MD&A if required by applicable securities legislation.

**See MDA statements for the 3-month period Ended September 30, 2023 as filed on SEDAR and the CSE site November 2, 2023**

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Quarterly Listing Statement.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 5 Quarterly Listing Statement is true.

Dated November 2, 2023.

Tatiana Kovaleva  
Name of Director or Senior Officer

"Tatiana Kovaleva"  
Signature

CFO  
Official Capacity

<b>Issuer Details</b> Name of Issuer		For Quarter Ended	Date of Report
Jolt Health Inc.		September 30, 2023	YY/MM/D 2023/11/02
Issuer Address			
Suite 1780, 355 Burrard St.			
City/Province/Postal Code		Issuer Fax No.	Issuer Telephone No.
Vancouver, BC V6C 2G8		( )	(604 )343-2977
Contact Name		Contact Position	Contact Telephone No.
Tatiana Kovaleva		CFO	778-233-7791
Contact Email Address		Web Site Address	
<a href="mailto:tkovaleva@ktbusiness2010.com">tkovaleva@ktbusiness2010.com</a>		<a href="https://www.jolt-health.com">https://www.jolt-health.com</a>	